echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Moffitt researchers developed a model to predict the outcome of immunotherapy in patients with non-small cell lung cancer

    Moffitt researchers developed a model to predict the outcome of immunotherapy in patients with non-small cell lung cancer

    • Last Update: 2021-09-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Tampa, Florida


    Measuring PD-L1 expression in patient tumors is a common biomarker that is often used to determine which patients should receive anti-pd1/PD-L1 treatment


    Researchers at Moffitt Cancer Center describe in a new article published in the journal JNCI Cancer Spectrum that they have created a predictive model that includes information calculated from computed tomography images that can identify those that may be Patients who do not respond to immunotherapy


    Moffitt’s research team did not analyze common tissue-based biomarkers, such as protein expression patterns, but evaluated the potential of using pre-treatment CT scan features combined with clinical data to identify markers related to the outcome of immunotherapy


    "Image-based quantitative features, or radiology, reflect the underlying pathophysiology and tumor heterogeneity as biomarkers of dominant tissues, because they can use standard treatments to quickly extract medical images and capture data from the entire tumor, rather than one A small number of tumor biopsies and laboratory tests," said Dr.


    The researchers analyzed the clinical and radiological characteristics of 180 patients with anti-pd1/PD-L1 non-small cell lung cancer with or without anti-ctla-4 treatment


    They found that among the 16 clinical features considered, serum albumin levels and the number of metastatic sites in patients were significantly correlated with overall survival


    The researchers validated their models in two other patient groups, and confirmed that the overall survival rate of the extremely high-risk group after immunotherapy was extremely low, with a 3-year overall survival rate of 0%, while the 3-year overall survival rate of the low-risk group was 0%.


    Schabath said: "These results indicate that very high-risk patients should avoid immunotherapy altogether, or use early-stage combination therapy that may produce improved responses


    10.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.